Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMLCTI5)

Drug Name

MK-8353 Drug Info

Synonyms

KPQQGHGDBBJGFA-QNGWXLTQSA-N; GTPL9974; SCHEMBL10236331; MK8353; (3S)-3-methylsulfanyl-1-[2-[4-[4-(1-methyl-1,2,4-triazol-3-yl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-2-oxoethyl]-N-[3-(6-propan-2-yloxypyridin-3-yl)-1H-indazol-5-yl]pyrrolidine-3-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 58282870
TTD Drug ID: DMLCTI5

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Ephrin type-B receptor 2 (EPHB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[1]
SEphB4-HSA	DMD8RU0	Kaposi sarcoma	2B57	Phase 2	[2]
KO-947	DMZMSBI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[3]
PMID23489211C20	DMDYC4J	Discovery agent	N.A.	Investigative	[4]
PMID19788238C66	DMCVJK9	Discovery agent	N.A.	Investigative	[5]
SNEWIQPRLPQH	DMYUH62	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Ephrin type-B receptor 2 (EPHB2)	TTKPV6O	EPHB2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	National Cancer Institute Drug Dictionary (drug name SEphB4-HSA).
3	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
4	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47.
5	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46.
6	Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13.